Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Earnings for Seelos Therapeutics, Inc. (SEEL)
Earnings in 2023 (TTM): $-37,882,000
According to Seelos Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-37,882,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Seelos Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-37,882,000 | $-37,882,000 |
| 2022 | $-73,534,000 | $-76,138,000 |
| 2021 | $-66,048,000 | $-67,533,000 |
| 2020 | $-19,101,000 | $-19,220,000 |
| 2019 | $-50,880,000 | $-50,383,000 |
| 2018 | $-9,218,000 | $-9,242,000 |
| 2017 | $-11,749,000 | $321 K |
| 2016 | $-7,433,000 | $-7,433,000 |
| 2015 | $-19,023,000 | $-19,023,000 |
| 2014 | $-22,477,000 | $-21,786,000 |
| 2013 | $-15,870,000 | $-16,938,000 |
| 2012 | $-25,044,000 | $-31,771,000 |
| 2011 | $-18,117,198 | $-18,117,198 |
| 2010 | $-29,508,346 | $-29,508,346 |
| 2009 | $-32,480,356 | $-32,042,562 |
| 2008 | $-6,108,855 | $-5,171,198 |
| 2007 | $-9,593,137 | $-8,787,228 |
| 2006 | $-8,610,650 | $-8,043,253 |
| 2005 | $-15,923,554 | $-15,442,438 |
| 2004 | $-17,562,695 | $-17,023,648 |
| 2003 | $-17,465,797 | $-17,233,864 |
| 2002 | $-27,884,164 | $-27,641,519 |
| 2001 | $-17,378,152 | $-16,174,861 |
| 2000 | $-9,976,002 | $-8,830,071 |
| 1999 | $-2,300,000 | $-2,500,000 |
| 1998 | $ | $-4,779,002 |
| 1997 | $ | $-3,857,466 |